66
Participants
Start Date
July 25, 2019
Primary Completion Date
March 31, 2026
Study Completion Date
February 21, 2030
CX 4945
CX-4945 is supplied as 200 mg capsules delivered orally as a formulated API
Memorial Sloan-Kettering Cancer Center, New York
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Children's National Medical Center, Washington D.C.
Children's Healthcare of Atlanta, Atlanta
University of Florida, Gainesville
St. Jude Children Research Hospital, Memphis
Nationwide Children's Hospital, Columbus
Cincinnati Children's Hospital Medical Center, Cincinnati
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Baylor College of Medicine, Houston
Children's Hospital of Los Angeles, Los Angeles
Stanford University and Lucile Packard Children's Hospital, Palo Alto
Senhwa Biosciences, Inc.
INDUSTRY
National Cancer Institute (NCI)
NIH
St. Jude Children's Research Hospital
OTHER
Pediatric Brain Tumor Consortium
NETWORK